Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Taiyen Biotech Co's Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$483 Mil. Therefore, Taiyen Biotech Co's EV-to-EBIT ratio for today is 9.20.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Taiyen Biotech Co's Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$741 Mil. Therefore, Taiyen Biotech Co's EV-to-EBITDA ratio for today is 6.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Taiyen Biotech Co's Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$3,190 Mil. Therefore, Taiyen Biotech Co's EV-to-Revenue ratio for today is 1.39.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Taiyen Biotech Co (TPE:1737) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$483 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$741 Mil.
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,190 Mil.
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$554 Mil.
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil.
Taiyen Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$245 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co Enterprise Value Related Terms
Taiyen Biotech Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1737 vs PG, CL, KVUE: Enterprise Value Comparison
For the Household & Personal Products subindustry, Taiyen Biotech Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co Enterprise Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Taiyen Biotech Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$4,443 Mil mean?
Taiyen Biotech Co (TPE:1737) has a Enterprise Value of NT$4,443 Mil as of Aug. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Taiyen Biotech Co and its competitors.
Is Taiyen Biotech Co's Enterprise Value too high?
Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Enterprise Value compare to PG and CL?
Taiyen Biotech Co's Enterprise Value of NT$4,443 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Consumer Packaged Goods company?
A good Enterprise Value depends on the Consumer Packaged Goods industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current Enterprise Value is NT$4,443 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.17, compared to a current price of NT$30.90 — trading 0.9% below its estimated fair value. The current Enterprise Value is NT$4,443 Mil. Taiyen Biotech Co's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Enterprise Value is NT$4,443 Mil as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$30.90 is trading 0.9% below its estimated GF Value™ of NT$31.17.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Enterprise Value: NT$4,443 Mil
GF Value™: NT$31.17 vs. price of NT$30.90 (0.9% below fair value)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score
Get the complete analysis for TPE:1737
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
